Business · Markets · 2 hrs ago
Newron completes patient recruitment for schizophrenia Phase 3 study
Newron Pharmaceuticals has completed patient recruitment for a Phase 3 schizophrenia study of its drug candidate Evenamide.
The study is called ENIGMA-TRS 1.
The recruitment milestone moves the trial forward, but it is not evidence that the drug works.
Investors had been watching for news about recruitment after Newron's shares rose 12.8% in the week covered by an earlier report.
That rise reflected hopes for progress, alongside continued debate about safety and how much the available data show.
The trial's results will be needed to assess Evenamide's effectiveness and safety.
The sources do not give a date for results or describe the next trial step.
Newron Pharmaceuticals has completed patient recruitment for a Phase 3 schizophrenia study, according to headlines published on October 22, 2026.
The study is identified in an earlier report as ENIGMA-TRS 1 and is testing the candidate drug Evenamide.
On October 17, Wallstreet Online reported that investors were anticipating news about completion of recruitment.
The same report said investors disagreed over Newron’s valuation, the significance of available data and the drug candidate’s prospects.
- Who
- Newron Pharmaceuticals.
- What
- It completed patient recruitment for a Phase 3 schizophrenia study.
- When
- Reported on October 22, 2026. The exact date recruitment was completed is not stated.
- Where
- Not stated.
- Why
- Not stated.
Optimistic investors
Skeptical investors
Study progress
Optimistic investors
Recruitment completion was viewed as a positive operational milestone.
Skeptical investors
Recruitment completion is not an immediate demonstration of the drug’s effectiveness.
Evenamide prospects
Optimistic investors
Some investors were hopeful about progress in the study programme.
Skeptical investors
Others questioned safety and the significance of the data discussed so far.
Wallstreet Online reported investor expectations of an announcement about recruitment completion for ENIGMA-TRS 1.
Headlines reported that Newron had completed patient recruitment for a Phase 3 schizophrenia study.
- Company
- Newron Pharmaceuticals
- Study phase
- Phase 3
- Study condition
- Schizophrenia
- Recruitment status
- Completed
- Candidate named in earlier report
- Evenamide
- Study name in earlier report
- ENIGMA-TRS 1